semaglutide black box warning These highlights do not include all the information needed to use OZEMPIC® safely and effectively. See full prescribing information for OZEMPIC. OZEMPIC (semaglutide) injection, for subcutaneous use Initial U.S. Approval: 2017 GLP-1 Drug Can Cause Rare,

The peptide structure degrades rapidly at elevated temperatures

Launch Phases Slow Start (Months 12 post-approval): Limited availability, specialty pharmacies only, high out-of-pocket costs before insurance coverage establishes

Some states require legislative approval to add coverage, and they would also need to develop clinical criteria

In sepsis-induced AKI models, PKM2 inhibition attenuates the activation of NLR family pyrin domain containing 3 (NLRP3) and absent in melanoma 2 (AIM2) inflammasomes, decreases the release of IL-1, IL-18, and HMGB1 by macrophages, and ultimately improves survival outcomes (Xie et al., 2016)